The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1503
Byvalson - A Beta Blocker/ARB Combination for Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Byvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol (Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB.

STANDARD TREATMENT — Most recent guidelines recommend a thiazide-type diuretic (chlorthalidone is preferred), a calcium channel blocker, an angiotensin-converting enzyme (ACE) inhibitor, or an ARB as initial therapy for hypertension in non-black patients. A thiazide-type diuretic or a calcium channel blocker is preferred for initial treatment of black patients, except those with chronic kidney disease or heart failure, who should receive an ACE inhibitor or an ARB. Beta blockers generally are no longer recommended as initial therapy, except in patients with a ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Byvalson - A Beta Blocker/ARB Combination for Hypertension
Article code: 1503a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian